文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FMISO PET/CT 导引放疗加量在非小细胞肺癌缺氧病灶中的长期随访:能否在不增加毒性下改善生存?

Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up].
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-03-13

这项开放标签、非随机、多中心 II 期试验在 54 例接受根治性放化疗的局部晚期非小细胞肺癌患者中用 18F-FMISO PET/CT 判断缺氧,阳性且满足危及器官约束者接受放疗加量(70-84 Gy),其余接受标准放疗(66 Gy)。3 年总生存率 48.5%、无进展生存率 28.8%;18F-FMISO 阳性者中位 OS 25.8 个月、阴性者未达到(p=0.01),中位 PFS 分别为 12 个月与 26.2 个月(p=0.048)。加量组未观察到显著晚期毒性,但加量对 OS 的获益因样本量小未达统计学意义。

要点

  • 18F-FMISO 阳性与较差预后相关:中位 OS 25.8 个月 vs 阴性者未达到(p=0.01)。
  • 18F-FMISO 阳性者中位 PFS 12 个月,阴性者 26.2 个月(p=0.048)。
  • 加量组未观察到显著晚期毒性,但加量对 OS 的获益需进一步试验验证。

核心结论

  • 在非小细胞肺癌患者中,18F-FMISO 摄取与提示预后不良的特征强相关。
  • 18F-FMISO 阳性患者接受放疗加量似可改善 OS 达 11.2 个月,但需进一步临床试验验证。

研究设计与样本

  • 开放标签、非随机、多中心 II 期临床试验,共评估 54 例接受根治性放化疗的非小细胞肺癌患者。
  • 用 18F-FMISO PET/CT 判断缺氧:阳性且无危及器官约束者接受放疗加量(70-84 Gy),其余接受标准放疗(66 Gy)。
  • 评估 3 年总生存、无进展生存与安全性。

主要发现

  • 3 年 OS 率为 48.5%,3 年 PFS 率为 28.8%。
  • 18F-FMISO 阳性患者中位 OS 为 25.8 个月,阴性患者未达到(p=0.01)。
  • 18F-FMISO 阳性与阴性患者中位 PFS 分别为 12 个月与 26.2 个月(p=0.048)。
  • 18F-FMISO 阳性患者中,未观察到 OS 与剂量相关差异(p=0.30);中位 OS 似偏向加量组(26.5 vs 15.3 个月,p=0.71)。
  • 接受放疗加量的患者未观察到显著晚期毒性。

关键数值与推荐

  • 18F-FMISO 阳性且无危及器官约束者接受放疗加量 70-84 Gy,其余接受标准放疗 66 Gy。
  • 18F-FMISO 阳性患者中位 OS 25.8 个月 vs 阴性者未达到(p=0.01)。
  • 18F-FMISO 阳性与阴性患者中位 PFS 12 个月 vs 26.2 个月(p=0.048)。
  • 18F-FMISO 阳性患者中加量 vs 未加量中位 OS 26.5 vs 15.3 个月(p=0.71)。

临床怎么用

  • 18F-FMISO PET/CT 可用于识别预后不良的缺氧非小细胞肺癌患者。
  • 对 18F-FMISO 阳性且满足危及器官约束的患者,放疗加量至 70-84 Gy 未观察到显著晚期毒性。
  • 加量对生存的获益尚需进一步临床试验证实,暂不能作为常规推荐。

局限性

  • 研究为非随机设计,样本量小(54 例),加量对 OS 的获益未达统计学意义。
  • 18F-FMISO 阳性患者中剂量比较可能因样本量小而未显示差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chemoradiotherapy is the reference curative-intent treatment for nonresectable locally advanced non-small-cell lung carcinoma (NSCLC), with unsatisfactory survival, partially due to radiation resistance in hypoxic tissues. The objective was to update survival and toxicity at 3 years following radiotherapy boost to hypoxic tumours in NSCLC patients treated with curative-intent chemoradiotherapy. METHODS: This was an open-label, nonrandomized, multicentre, phase II clinical trial. 18F-Fluoromisonidazole (18F-FMISO) PET/CT was used to determine the hypoxic profile of the patients. 18F-FMISO-positive patients and those without organ-at-risk constraints received a radiotherapy boost (70-84 Gy); the others received standard radiotherapy (66 Gy). Overall survival (OS), progression-free survival (PFS) and safety were assessed. RESULTS: A total of 54 patients were evaluated. OS and PFS rates at 3 years were 48.5% and 28.8%, respectively. The median OS in the 18F-FMISO-positive patients was 25.8 months and was not reached in the 18F-FMISO-negative patients (p = 0.01). A difference between the groups was also observed for PFS (12 months vs. 26.2 months, p = 0.048). In 18F-FMISO-positive patients, no difference was observed in OS in relation to dose, probably because of the small sample size (p = 0.30). However, the median OS seemed to be in favour of patients who received the radiotherapy boost (26.5 vs. 15.3 months, p = 0.71). In patients who received the radiotherapy boost, no significant late toxicities were observed. CONCLUSION: 18F-FMISO uptake in NSCLC patients is strongly associated with features indicating a poor prognosis. In 18F-FMISO-positive patients, the radiotherapy boost seemed to improve the OS by 11.2 months. A further clinical trial is needed to investigate the efficacy of a radiotherapy boost in patients with hypoxic tumours.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Vera P, Mihailescu SD, Lequesne J, et al. Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]. Eur J Nucl Med Mol Imaging. 2019. PMID: 30868230. doi:10.1007/s00259-019-04285-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。